此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

增加转移性 DTC 中 RAI 摄取的靶向治疗

2026年11月17日 更新者:Children's Hospital of Philadelphia

增加转移性分化型甲状腺癌患者 RAI 摄取的靶向治疗

Papillary thyroid cancer (PTC) is a common type of differentiated thyroid cancer (DTC) in children and represents the second most common cancer in adolescent females. Recently targeted drugs that block many of the genetic drivers of DTC have become available. While Investigators know that these drugs shrink DTC tumors in many cases, the impact on radioactive iodine (RAI) avidity has not been systematically studied.

研究概览

地位

主动,不招人

条件

干预/治疗

详细说明

This is an observational cohort study that will enroll patients with DTC metastatic to the lungs who will receive oncogene-specific targeted therapy as part of routine clinical care or a separate therapeutic clinical trial. After approximately 4 weeks of therapy, patients will have a whole body scan to determine the change in RAI-avidity of their tumor from baseline. Subsequent therapy will be at the discretion of the treating physician or according to the therapeutic trial on which the patient is enrolled.

研究类型

观察性的

注册 (估计的)

32

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • New South Wales
      • Sydney、New South Wales、澳大利亚
        • Children's Hospital Westmead
    • California
      • San Francisco、California、美国、94143
        • University of California San Francisco
    • Georgia
      • Atlanta、Georgia、美国、30322
        • Emory University School of Medicine
    • Pennsylvania
      • Philadelphia、Pennsylvania、美国、19104
        • Children's Hospital of Philadelphia
    • Tennessee
      • Memphis、Tennessee、美国、38105
        • St. Jude Children's Research Hospital
    • Texas
      • Houston、Texas、美国、77030
        • MD Anderson Cancer Center
      • Houston、Texas、美国、77030
        • Texas Children's Hospital
    • Washington
      • Seattle、Washington、美国、98105
        • Seattle Children's Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

1秒 及以上 (孩子、成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

This study will enroll children and adolescents with differentiated thyroid cancer with pulmonary metastases who are planned to receive oncogene-specific targeted therapy.

描述

Inclusion Criteria (Prospective Cohort):

  1. Patients with a histologic diagnosis of differentiated thyroid cancer

  2. Presence of an neurotrophic tyrosine kinase receptors (NTRK)-fusion, RET-fusion, anaplastic lymphoma kinase (ALK)-fusion, BRAF V600 mutation, BRAF-fusion or other targetable alteration identified in a Clinical Laboratory Improvement Amendments/College of American Pathologists (CLIA/CAP) laboratory

  3. Anatomically evaluable disease on chest Computed tomography (CT) meeting oneo f the following criteria (obtained within 180 days of enrollment):

    1. multiple (10 or more) noncalcified solid pulmonary nodules visible on CT and/or
    2. enlarging, discrete pulmonary nodules visible on CT of any number consistent with metastatic disease
  4. Patients for whom systemic therapy with an oncogene-specific kinase inhibitor is planned from commercial supply or as part of a separate therapeutic clinical trial (that does not include data sharing with this protocol)/compassionate access protocol/single patient investigational new drug (IND). Such agents include, but are not limited to:

    1. Larotrectinib, entrectinib, selitrectinib, and repotrectinib for NTRK fusions
    2. Selpercatinib and pralsetinib for RET fusions
    3. Crizotinib, lorlatinib, repotrectinib, and alectinib for ALK fusions
    4. Dabrafenib and/or trametinib for BRAF V600 mutations
    5. Oncogene-specific kinase inhibitors other than those specifically delineated above must be approved by the overall study PI prior to enrollment

Inclusion Criteria (Data Sharing Cohort):

1. Patients enrolled on other oncogene-specific targeted therapy trials who undergo whole body thyroid scan approximately 28 days after beginning targeted therapy and agree to data sharing as part of the consent process for that trial.

Exclusion Criteria (All Cohorts):

  1. No prior oncogene-specific targeted therapy allowed. However, patients may enroll within 4 weeks of starting oncogene-specific therapy if a pre-therapy WBS is available. Prior therapy with non-oncogene specific multi-thyrosine kinase inhibitors (such as sorafenib, lenvatinib, and/or cabozantanib) is allowed.
  2. Females who are pregnant or breastfeeding are excluded due to the potential risks of the RAI used in the WBS to the fetus/neonate.
  3. Patients who require sedation/general anesthesia to complete a WBS are excluded.
  4. U.S. Military Personnel are excluded due to the Children's Hospital of Philadelphia (CHOP) Institutional Review Board (IRB) requirements.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
干预/治疗
Prospective Cohort

Patients with differentiated thyroid cancer for whom oncogene-specific targeted therapy is planned from commercial supply or as part of a separate therapeutic trial

Patients will receive oncogene-specific molecularly targeted therapy independently of this protocol either via commercial supply of an FDA approved agent, or as part of a separate therapeutic clinical trial/compassionate use protocol/single patient investigational new drug (IND).

During screening, patients will undergo a baseline RAI-whole body scan (WBS) to assess RAI-avidity of their tumor per standard of care. Following approximately 28 days of targeted therapy, the WBS will be repeated to determine whether this therapy is associated with an increase in RAI-avidity of their tumor.

Data Sharing Cohort

Patients with differentiated thyroid cancer enrolled on other oncogene-specific targeted therapy trials who undergo whole body thyroid scan approximately 28 days after beginning targeted therapy and agree to data sharing

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Proportion of patients with increased tumor RAI-avidity after receiving oncogene-specific, targeted therapy
大体时间:up to 5 years

The primary outcome measure is to determine the proportion of patients with differentiated thyroid cancer metastatic to the lungs for whom oncogene-specific, targeted therapy increases tumor RAI-avidity.

up to 5 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

合作者

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2021年7月16日

初级完成 (估计的)

2027年7月1日

研究完成 (估计的)

2028年7月1日

研究注册日期

首次提交

2021年8月23日

首先提交符合 QC 标准的

2021年8月23日

首次发布 (实际的)

2021年8月27日

研究记录更新

最后更新发布 (实际的)

2026年11月20日

上次提交的符合 QC 标准的更新

2026年11月17日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • 21-018612

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.